Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus chemotherapy in early relapsing recurrent triple-negative breast cancer
NCT03371017Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2018
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 28
01
Overview
A Phase 3 trial of atezolizumab in triple-negative breast cancer (TNBC), sponsored by Roche. Started Jan 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03371017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03371017.